Akebia Therapeutics (NASDAQ:AKBA)‘s stock had its “buy” rating reissued by Mizuho in a note issued to investors on Tuesday. They currently have a $24.00 price target on the biopharmaceutical company’s stock. Mizuho’s price target would suggest a potential upside of 64.84% from the company’s current price.

The analysts wrote, “We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged.””

AKBA has been the topic of a number of other research reports. Royal Bank of Canada restated a “hold” rating and issued a $17.00 target price on shares of Akebia Therapeutics in a report on Thursday, November 2nd. Zacks Investment Research upgraded Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a report on Monday, November 13th. HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, November 15th. ValuEngine lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BTIG Research initiated coverage on Akebia Therapeutics in a report on Thursday, December 7th. They issued a “buy” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $22.20.

Shares of Akebia Therapeutics (NASDAQ AKBA) opened at $14.56 on Tuesday. Akebia Therapeutics has a one year low of $8.58 and a one year high of $20.25.

Hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in shares of Akebia Therapeutics in the second quarter valued at approximately $159,000. Macquarie Group Ltd. bought a new stake in Akebia Therapeutics during the third quarter worth $183,000. Teacher Retirement System of Texas bought a new stake in Akebia Therapeutics during the fourth quarter worth $188,000. Campbell & CO Investment Adviser LLC bought a new stake in Akebia Therapeutics during the third quarter worth $200,000. Finally, Caxton Associates LP bought a new stake in Akebia Therapeutics during the third quarter worth $246,000. Institutional investors own 62.16% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Akebia Therapeutics (AKBA) Earns “Buy” Rating from Mizuho” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/15/akebia-therapeutics-akba-earns-buy-rating-from-mizuho.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.